Merck & Co Inc · 8-K · For 10/18/02 · EX-99.B

Filed On 10/18/02 4:14pm ET   ·   SEC File 1-03305   ·   Accession Number 950123-2-9793

Current Report   ·   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         3     11K 
 2: EX-99.A     Press Release                                         13     49K 
 3: EX-99.B     Certain Supplemental Information                       7     28K 

EX-99.B   ·   Certain Supplemental Information

EX-99.B
1st Page of 7
TOC
Top
Previous
Next
Bottom
Just 1st
 
Sponsored Ads...


                                                                   Exhibit 99(b)

 MERCK & CO., INC.
GROSS PRODUCT SALES DETAIL

                                                                [Download Table]

                                         3Q `02 vs. 3Q `01                    
                      --------------------------------------------------------
                      TOTAL     TOTAL      U.S.      U.S.    FOREIGN   FOREIGN
     PRODUCT          % CHG       $       % CHG       $       % CHG       $   
--------------------  -----     -----      ----      ----    -------   -------
                                                                              
VIOXX                    2%    $  810      -4%     $  600       24%     $210  
ARCOXIA                N/M         10     N/M          --      N/M        10  
VASOTEC / VASERETIC    -24%       185     N/M         (10)      -9%      195  
PRINIVIL / PRINZIDE    -38%       165     -43%        140       25%       25  
COZAAR / HYZAAR          8%       585      -5%        260       23%      325  
MEVACOR                -50%        55     -56%         40      -25%       15  
ZOCOR                   11%     1,925       6%      1,340       24%      585  
AGGRASTAT                0%        25       0%         15      N/M        10  
SINGULAIR                9%       380       0%        270       38%      110  
MAXALT                  36%        95      25%         75      100%       20  
PROPECIA                 0%        55      20%         30      -17%       25  
PROSCAR                 18%       165      36%         95        0%       70  
PRIMAXIN                11%       155      38%         55        0%      100  
INVANZ                 N/M          5     N/M          --      N/M         5  
CANCIDAS               N/M         30     N/M          20      N/M        10  
PEPCID                 -57%        15     -75%          5      -33%       10  
FOSAMAX                 11%       500      -2%        315       42%      185  
CRIXIVAN/STOCRIN       -39%        70     -69%         20        0%       50  
TIMOPTIC/TIMOPTIC XE   -20%        40     -67%          5        0%       35  
TRUSOPT/COSOPT          15%       115      22%         55        9%       60  
HEPATITIS VACCINES     -15%        85     -22%         70       50%       15  
VIRAL VACCINES          -9%       145      -7%        140      -50%        5  
OTHER VACCINES         N/M         55     N/M          45      N/M        10  

NOTE: Product sales rounded to the nearest $5 million.                          
N / M - Not Meaningful                                                          

EX-99.B
2nd Page of 7
TOC
1st
Previous
Next
Bottom
Just 2nd

                                                                   Exhibit 99(b)

 MERCK & CO., INC.
GROSS PRODUCT SALES DETAIL

                                                        [Enlarge/Download Table]

                                            9 MONTHS 2002 OVER 2001                       
                        ------------------------------------------------------------------
                        TOTAL       TOTAL        U.S.        U.S.      FOREIGN     FOREIGN
        PRODUCT         % CHG         $         % CHG         $        % CHG          $   
----------------------  -----       -----        ----        ----      -------     -------
                                                                                          
VIOXX                     15%      $2,305         12%      $1,715         24%      $  590 
ARCOXIA                  N/M           20        N/M           --        N/M           20 
VASOTEC / VASERETIC      -28%         580        N/M           --        -16%         580 
PRINIVIL / PRINZIDE      -12%         830        -12%         765         -7%          65 
COZAAR / HYZAAR           12%       1,610         16%         740          9%         870 
MEVACOR                  -51%         190        -56%         145        -25%          45 
ZOCOR                     12%       5,155         11%       3,555         12%       1,600 
AGGRASTAT                 -6%          80        -27%          40         33%          40 
SINGULAIR                  7%       1,100          1%         805         31%         295 
MAXALT                    15%         235          9%         180         38%          55 
PROPECIA                  -3%         155        -12%          75          7%          80 
PROSCAR                    0%         410          0%         210          0%         200 
PRIMAXIN                  -2%         430          4%         135         -5%         295 
INVANZ                   N/M           10        N/M            5        N/M            5 
CANCIDAS                 N/M           70        N/M           45        N/M           25 
PEPCID                   -86%          45        -93%          20        -50%          25 
FOSAMAX                   32%       1,700         30%       1,220         37%         480 
CRIXIVAN/STOCRIN         -33%         225        -43%          85        -24%         140 
TIMOPTIC/TIMOPTIC XE     -24%         125        -56%          20        -13%         105 
TRUSOPT/COSOPT             8%         325          7%         155         10%         170 
HEPATITIS VACCINES       -17%         225        -18%         200          0%          25 
VIRAL VACCINES             4%         440          8%         425        -50%          15 
OTHER VACCINES           N/M           95        N/M           65        N/M           30 

NOTE: Product sales rounded to the nearest $5 million.                          
N / M - Not Meaningful                                                          

EX-99.B
3rd Page of 7
TOC
1st
Previous
Next
Bottom
Just 3rd

                                                                   Exhibit 99(b)
 MERCK & CO., INC.
NET PRODUCT SALES DETAIL

                                                        [Enlarge/Download Table]

                                              3Q `02 vs. 3Q `01                        
                      -----------------------------------------------------------------
                      TOTAL      TOTAL         U.S.       U.S.      FOREIGN     FOREIGN
      PRODUCT         % CHG        $          % CHG        $        % CHG          $   
--------------------  -----      -----         ----       ----      -------     -------
                                                                                       
VIOXX                    3%      $  755         -3%     $  545         24%      $  210 
ARCOXIA                N/M           10        N/M          --        N/M           10 
VASOTEC / VASERETIC    -24%         185        N/M         (10)        -9%         195 
PRINIVIL / PRINZIDE    -24%          80        -35%         55         25%          25 
COZAAR / HYZAAR          8%         550         -8%        225         23%         325 
MEVACOR                -33%          30        -40%         15        -25%          15 
ZOCOR                    9%       1,470          1%        885         24%         585 
AGGRASTAT              -20%          20        -33%         10        N/M           10 
SINGULAIR               11%         350          2%        240         38%         110 
MAXALT                  23%          80          9%         60        N/M           20 
PROPECIA                 0%          55         20%         30        -17%          25 
PROSCAR                 19%         155         42%         85          0%          70 
PRIMAXIN                11%         150         43%         50          0%         100 
INVANZ                 N/M            5        N/M          --        N/M            5 
CANCIDAS               N/M           30        N/M          20        N/M           10 
PEPCID                 -50%          10       -100%         --        -33%          10 
FOSAMAX                  9%         455         -5%        270         37%         185 
CRIXIVAN/STOCRIN       -41%          65        -75%         15          0%          50 
TIMOPTIC/TIMOPTIC XE   -20%          40        -67%          5          0%          35 
TRUSOPT/COSOPT          11%         105         13%         45          9%          60 
HEPATITIS VACCINES      -7%          65        -17%         50        N/M           15 
VIRAL VACCINES          -6%         145         -3%        140        N/M            5 
OTHER VACCINES         N/M           80        N/M          70        N/M           10 

NOTE: Product sales rounded to the nearest $5 million.                          
N / M - Not Meaningful                                                          

EX-99.B
4th Page of 7
TOC
1st
Previous
Next
Bottom
Just 4th

                                                                   Exhibit 99(b)

 MERCK & CO., INC.
NET PRODUCT SALES DETAIL

                                                        [Enlarge/Download Table]

                                          9 MONTHS 2002 OVER 2001                      
                      -----------------------------------------------------------------
                      TOTAL      TOTAL        U.S.        U.S.      FOREIGN     FOREIGN
      PRODUCT         % CHG        $         % CHG         $         % CHG         $   
-------------------   -----      -----        ----        ----      -------     -------
                                                                                       
VIOXX                   17%      $2,145         14%     $1,555         24%      $  590 
ARCOXIA                N/M           20        N/M          --        N/M           20 
VASOTEC / VASERETIC    -27%         580       -100%         --        -16%         580 
PRINIVIL / PRINZIDE    -12%         470        -13%        405         -7%          65 
COZAAR / HYZAAR         10%       1,505         11%        635          9%         870 
MEVACOR                -58%          90        -71%         45        -25%          45 
ZOCOR                    8%       3,840          5%      2,240         12%       1,600 
AGGRASTAT               -6%          75        -30%         35         33%          40 
SINGULAIR                5%         995         -3%        700         31%         295 
MAXALT                  14%         205          7%        150         38%          55 
PROPECIA                -3%         155        -12%         75          7%          80 
PROSCAR                 -3%         385         -5%        185          0%         200 
PRIMAXIN                -5%         410         -4%        115         -5%         295 
INVANZ                 N/M           10        N/M           5        N/M            5 
CANCIDAS               N/M           65        N/M          40        N/M           25 
PEPCID                 -85%          40        -93%         15        -50%          25 
FOSAMAX                 29%       1,555         26%      1,075         35%         480 
CRIXIVAN/STOCRIN       -33%         215        -44%         75        -24%         140 
TIMOPTIC/TIMOPTIC XE   -22%         125        -50%         20        -13%         105 
TRUSOPT/COSOPT           5%         305          0%        135         10%         170 
HEPATITIS VACCINES     -19%         170        -22%        145          0%          25 
VIRAL VACCINES           4%         430          8%        415        N/M           15 
OTHER VACCINES         N/M          165        N/M         135        N/M           30 

NOTE: Product sales rounded to the nearest $5 million.                          
N / M - Not Meaningful                                                          

EX-99.B
5th Page of 7
TOC
1st
Previous
Next
Bottom
Just 5th

                                                                   Exhibit 99(b)

 MERCK & CO., INC.
CONSOLIDATED
 THIRD QUARTER

                                                                [Download Table]

                                    3Q `02        3Q `01     % CHG.
                                    ------        ------     ------
                                                                   
TOTAL SALES                        $ 12,892.9   $ 11,919.6      8% 
                                   ----------   ----------         

TOTAL COSTS, EXPENSES, & OTHER     $ 10,201.6   $  9,136.5         
                                   ----------   ----------         
    Materials & Production            8,080.1      7,082.8         
    Marketing & Administrative        1,562.7      1,525.3         
    Research & Development              676.9        590.3         
    Equity Income From Affiliates      (188.7)      (164.1)        
    Other (Income)/Expense, Net          70.6        102.2         

PRE-TAX INCOME                     $  2,691.3   $  2,783.1         

TAXES                              $    807.3   $    834.9         
TAX RATE                                 30.0%        30.0%        

NET INCOME                         $  1,884.0   $  1,948.2    -3%  

EPS - ASSUMING DILUTION            $     0.83   $     0.84    -1%  

AVG. # SHARES - ASSUMING DILUTION     2,265.9      2,312.4         

                                                                [Download Table]

                                   3Q `02     % CHG.       VOL      PX      FX 
                                   -------    -------      ----    ----    ----
                                                                               
TOTAL SALES                        $12,890        8%          0       7       1
                                   -------     ----        ----    ----    ----

    Total Pharmaceutical Sales       5,515        1%         -2       2       1
                                   -------     ----        ----    ----    ----
        U.S.                         3,390       -6%        -12       6       0
        Foreign                      2,125       14%         14      -3       3

    Other Medco Sales                7,375       14%                           

EX-99.B
6th Page of 7
TOC
1st
Previous
Next
Bottom
Just 6th

                                                                   Exhibit 99(b)

 MERCK & CO., INC.
CONSOLIDATED
NINE MONTHS YEAR TO DATE

                                                                [Download Table]

                                      2002         2001        % CHG.  
                                   ----------   ----------   ----------
                                                                       
TOTAL SALES                        $ 37,871.9   $ 35,157.8        8%   
                                   ----------   ----------             

TOTAL COSTS, EXPENSES, & OTHER     $ 30,358.1   $ 27,413.7             
                                   ----------   ----------             
  Materials & Production             24,353.5     21,334.1             
  Marketing & Administrative          4,505.3      4,669.0             
  Research & Development              1,838.4      1,740.0             
  Equity Income From Affiliates        (550.7)      (557.8)            
  Other (Income)/Expense, Net           211.6        228.4             

PRE-TAX INCOME                     $  7,513.8   $  7,744.1             

TAXES                              $  2,254.1   $  2,323.2             
TAX RATE                                 30.0%        30.0%            

NET INCOME                         $  5,259.7   $  5,420.9       -3%   

EPS - ASSUMING DILUTION            $     2.31   $     2.33       -1%   

AVG. # SHARES - ASSUMING DILUTION     2,281.0      2,329.1             

                                                                [Download Table]

                                   2002     % CHG.      VOL      PX      FX 
                                 -------    -----       ----    ----    ----
                                                                            
TOTAL SALES                      $37,870        8%         2       6       0
                                 -------     ----       ----    ----    ----

  Total Pharmaceutical Sales      15,570       -1%         0       0      -1
                                 -------     ----       ----    ----    ----
      U.S.                         9,690       -4%        -6       2       0
      Foreign                      5,880        4%         9      -2      -3

  Other Medco Sales               22,300       15%                          

EX-99.B
Last Page of 7
TOC
1st
Previous
Next
Bottom
Just 7th

                                                                   Exhibit 99(b)

 MERCK & CO., INC.
 OTHER FINANCIAL DISCLOSURES
 THIRD QUARTER
2002

================================================================================

OTHER (INCOME)/EXPENSE, NET                                                     

                                                                [Download Table]

                                           3Q `02    3Q `01   YTD 2002  YTD 2001
                                           ------    ------   --------  --------
                                                                                
INTEREST INCOME                           $(107.3)  $(114.6)  $(311.2)  $(380.3)
INTEREST EXPENSE                             99.9     121.8     292.7     355.2 
EXCHANGE (GAINS)/LOSSES                       8.3       1.5      10.9     (18.6)
MINORITY INTERESTS                           59.1      72.3     169.7     218.3 
AMORTIZATION OF GOODWILL AND INTANGIBLES     51.1      83.7     153.5     244.8 
Other, net                                  (40.5)    (62.5)   (104.0)   (191.0)
                                          -------   -------   -------   ------- 
TOTAL                                     $  70.6   $ 102.2   $ 211.6   $ 228.4 
                                          -------   -------   -------   ------- 

================================================================================

JOINT VENTURE SALES DETAIL                                                      

All sales reported here are end-market JV sales, presented on a "NET" basis,    
rounded to the nearest $5 million.                                              

                                                                [Download Table]

MERIAL                                  3Q `02   3Q `01   YTD 2002   YTD 2001
------                                  ------   ------   --------   --------
                                                                             
IVOMEC, HEARTGARD, other avermectins     $130     $130     $  350     $  365 
FRONTLINE                                 150      100        410        340 
Biologicals                                90       85        275        255 
Other Animal Health                        40       45        130        145 
Poultry Genetics                           55       50        165        155 
                                         ----     ----     ------     ------ 
TOTAL MERIAL SALES                       $465     $410     $1,330     $1,260 
                                         ----     ----     ------     ------ 

                                                                [Download Table]

AVENTIS PASTEUR-MSD                     3Q `02   3Q `01   YTD 2002   YTD 2001
------                                  ------   ------   --------   --------
                                                                             
HEPATITIS VACCINES                       $ 20     $ 20     $   50     $   70 
VIRAL VACCINES                             10       10         25         35 
Other Vaccines                            175      125        325        265 
                                         ----     ----     ------     ------ 
TOTAL AP-MSD SALES                       $205     $155     $  400     $  370 
                                         ----     ----     ------     ------ 

================================================================================

TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (IN MILLIONS)                            

                                                                [Download Table]

                             2002                                          
                                                   MAIL    RETAIL     TOTAL
                                                   ----    ------     -----
                                                                           
FIRST QUARTER                                        20       121       141
SECOND QUARTER                                       21       119       140
THIRD QUARTER                                        20       110       130
                                                   ----      ----      ----
YEAR TO DATE                                         61       350       411
                                                   ----      ----      ----

                                                                [Download Table]

                             2001                                          
                                                   MAIL    RETAIL     TOTAL
                                                   ----    ------     -----
                                                                           
FIRST QUARTER                                        18       120       138
SECOND QUARTER                                       18       115       133
THIRD QUARTER                                        19       110       129
                                                   ----      ----      ----
YEAR TO DATE                                         55       345       400
                                                   ----      ----      ----